These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

355 related items for PubMed ID: 8615176

  • 1. A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients.
    Rascol O, Lees AJ, Senard JM, Pirtosek Z, Brefel C, Montastruc JL, Fuell D.
    Adv Neurol; 1996; 69():531-4. PubMed ID: 8615176
    [No Abstract] [Full Text] [Related]

  • 2. Ropinirole in the symptomatic treatment of Parkinson's disease.
    Brooks DJ, Torjanski N, Burn DJ.
    J Neural Transm Suppl; 1995; 45():231-8. PubMed ID: 8748630
    [Abstract] [Full Text] [Related]

  • 3. [Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy].
    Buchwald B, Angersbach D, Jost WH.
    Fortschr Neurol Psychiatr; 2007 Apr; 75(4):236-41. PubMed ID: 17427044
    [Abstract] [Full Text] [Related]

  • 4. Pramipexole, ropinirole, and mania in Parkinson's disease.
    Singh A, Althoff R, Martineau RJ, Jacobson J.
    Am J Psychiatry; 2005 Apr; 162(4):814-5. PubMed ID: 15800169
    [No Abstract] [Full Text] [Related]

  • 5. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
    Stocchi F, Marconi S.
    Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Ropinirole: new preparation. Wait for more convincing data.
    Prescrire Int; 1998 Apr; 7(34):36-8. PubMed ID: 10183378
    [Abstract] [Full Text] [Related]

  • 11. A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease.
    Brooks DJ, Abbott RJ, Lees AJ, Martignoni E, Philcox DV, Rascol O, Roos RA, Sagar HJ.
    Clin Neuropharmacol; 1998 Apr; 21(2):101-7. PubMed ID: 9579296
    [Abstract] [Full Text] [Related]

  • 12. Dopaminergic agonists in the treatment of Parkinson's disease: a review.
    Piccoli F, Riuggeri RM.
    J Neural Transm Suppl; 1995 Apr; 45():187-95. PubMed ID: 8748625
    [Abstract] [Full Text] [Related]

  • 13. Combination of two different dopamine agonists in the management of Parkinson's disease.
    Stocchi F, Berardelli A, Vacca L, Thomas A, De Pandis MF, Modugno N, Valente M, Ruggieri S.
    Neurol Sci; 2002 Sep; 23 Suppl 2():S115-6. PubMed ID: 12548370
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. An open-label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease.
    Lyons KE, Pahwa R.
    Mov Disord; 2009 Oct 30; 24(14):2121-7. PubMed ID: 19768728
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effects of ropinirole prolonged-release on sleep disturbances and daytime sleepiness in Parkinson disease.
    Dusek P, Busková J, Růzicka E, Majerová V, Srp A, Jech R, Roth J, Sonka K.
    Clin Neuropharmacol; 2010 Jul 30; 33(4):186-90. PubMed ID: 20661025
    [Abstract] [Full Text] [Related]

  • 20. Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test.
    Fabbrini G, Barbanti P, Aurilia C, Pauletti C, Meco G.
    Funct Neurol; 2002 Jul 30; 17(4):199-201. PubMed ID: 12675263
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.